Clene Inc. (CLNN) |
|
1.65 0.03 (1.85%)
|
02-03 15:40 |
|
Open: |
1.64 |
Pre. Close: |
1.62 |
|
High:
|
1.67 |
Low:
|
1.62 |
|
Volume:
|
92,637 |
Market Cap:
|
122(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 3:16:11 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 1.98 One year: 2.31 |
| Support: |
Support1: 1.21 Support2: 0.92 |
| Resistance: |
Resistance1: 1.7 Resistance2: 1.98 |
| Pivot: |
1.51 |
| Moving Average: |
MA(5): 1.58 MA(20): 1.4
MA(100): 1.45  MA(250): 2.4 |
| MACD: |
MACD(12,26): 0.1 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 84.7 %D(3): 80.8 |
| RSI: |
RSI(14): 66.6 |
| 52-week: |
High: 5.13 Low: 0.87 |
| Average Vol(K): |
3-Month: 177 (K) 10-Days: 125 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CLNN ] has closed below upper band by 15.1%. Bollinger Bands are 40.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.68 - 1.69 |
1.69 - 1.69 |
|
Low:
|
1.58 - 1.59 |
1.59 - 1.6 |
|
Close:
|
1.61 - 1.62 |
1.62 - 1.63 |
|
Company Description |
|
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah. |
Headline News |
Mon, 23 Jan 2023
Clene Inc. (NASDAQ:CLNN) Sees Large Drop in Short Interest - MarketBeat
Wed, 18 Jan 2023
Private companies are Clene Inc.'s (NASDAQ:CLNN) biggest owners and were rewarded after market cap rose by US$29m last week - Simply Wall St
Wed, 11 Jan 2023
Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23 - Marketscreener.com
Sun, 08 Jan 2023
These 10 Stocks Had The Most Insider Buying Activity During The ... - Nasdaq
Wed, 28 Dec 2022
Clene's COVID-19 Candidate Shows No Substantial Symptom Resolution In Phase 2 Trial - Yahoo Finance
Mon, 03 Oct 2022
Clene Stock Falls As Lead Asset Fails To Show Survival, Function Benefit In Amyotrophic Lateral Sclerosis Trial - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
74 (M) |
|
% Held by Insiders
|
2.558e+007 (%) |
|
% Held by Institutions
|
62 (%) |
|
Shares Short
|
2,410 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.986e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-11 |
|
Return on Assets (ttm)
|
596.7 |
|
Return on Equity (ttm)
|
-58.3 |
|
Qtrly Rev. Growth
|
438000 |
|
Gross Profit (p.s.)
|
323.33 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
2.41111e+006 |
|
Qtrly Earnings Growth
|
0.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-41 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.98 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
2.26e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
